Cost per median overall survival month associated with abiraterone acetate and enzalutamide for treatment of patients with metastatic castration-resistant prostate cancer.

Pilon, Dominic

Cost per median overall survival month associated with abiraterone acetate and enzalutamide for treatment of patients with metastatic castration-resistant prostate cancer. [electronic resource] - Journal of medical economics Aug 2016 - 777-84 p. digital

Publication Type: Journal Article

1941-837X

10.3111/13696998.2016.1173042 doi


Abiraterone Acetate--economics
Adult
Aged
Aged, 80 and over
Antineoplastic Agents--economics
Benzamides
Clinical Trials, Phase III as Topic
Costs and Cost Analysis
Disease Progression
Disease-Free Survival
Drug Therapy, Combination
Humans
Male
Middle Aged
Neoplasm Metastasis
Nitriles
Phenylthiohydantoin--analogs & derivatives
Prednisone--economics
Prostate-Specific Antigen
Prostatic Neoplasms, Castration-Resistant--drug therapy